SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : wla(warner lambert)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Linda Pearson who wrote (123)12/1/1997 9:58:00 PM
From: George Dawson   of 942
 
Linda,

This was a different excerpt from the article:

"It strengthened its recommendations about the drug, known generically
as troglitazone, after reports that some people on the drug had suffered
liver failure and three had died."

It may be an idiosyncratic reaction, but the overall impression is that there more concern and uncertainty. As an example, there are drugs taken by 2 - 3 x as many people for more years, but cause this many deaths from liver failure. I think it also explains why WLA is saying that the risk is much less than the risk from diabetes, while the drug as withdrawn temporarily in the U.K.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News